ARTICLE | Distillery Therapeutics

Therapeutics: Histone deacetylase 8 (HDAC8)

October 22, 2015 7:00 AM UTC

In vitro and mouse studies suggest inhibiting HDAC8 could help treat AML. In primary human AML leukemic stem cells, an HDAC8 inhibitor decreased proliferation and increased apoptosis compared with vehicle. In a mouse model of AML, a tool compound that inhibits HDAC8 decreased the number of AML cells in the bone marrow and spleen compared with vehicle. In mice, adoptive transfer of leukemia stem cells from the HDAC8 inhibitor-treated mouse model of AML decreased incidence of leukemia and increased survival compared with transfer of cells from vehicle-treated mice. Next steps could include testing HDAC8 inhibition in additional leukemia models...